Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Microsc Microanal ; 30(3): 521-538, 2024 Jul 04.
Artigo em Inglês | MEDLINE | ID: mdl-38709559

RESUMO

Leishmaniasis is a neglected tropical disease (endemic in 99 countries) caused by parasitic protozoa of the genus Leishmania. As treatment options are limited, there is an unmet need for new drugs. The hydroxynaphthoquinone class of compounds demonstrates broad-spectrum activity against protozoan parasites. Buparvaquone (BPQ), a member of this class, is the only drug licensed for the treatment of theileriosis. BPQ has shown promising antileishmanial activity but its mode of action is largely unknown. The aim of this study was to evaluate the ultrastructural and physiological effects of BPQ for elucidating the mechanisms underlying the in vitro antiproliferative activity in Leishmania donovani. Transmission and scanning electron microscopy analyses of BPQ-treated parasites revealed ultrastructural effects characteristic of apoptosis-like cell death, which include alterations in the nucleus, mitochondrion, kinetoplast, flagella, and the flagellar pocket. Using flow cytometry, laser scanning confocal microscopy, and fluorometry, we found that BPQ induced caspase-independent apoptosis-like cell death by losing plasma membrane phospholipid asymmetry and cell cycle arrest at sub-G0/G1 phase. Depolarization of the mitochondrial membrane leads to the generation of oxidative stress and impaired ATP synthesis followed by disruption of intracellular calcium homeostasis. Collectively, these findings provide valuable mechanistic insights and demonstrate BPQ's potential for development as an antileishmanial agent.


Assuntos
Antiprotozoários , Apoptose , Leishmania donovani , Mitocôndrias , Naftoquinonas , Leishmania donovani/efeitos dos fármacos , Leishmania donovani/fisiologia , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/ultraestrutura , Apoptose/efeitos dos fármacos , Antiprotozoários/farmacologia , Naftoquinonas/farmacologia , Caspases/metabolismo , Microscopia Eletrônica de Varredura , Microscopia Eletrônica de Transmissão
2.
Eur J Med Chem ; 257: 115524, 2023 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-37290183

RESUMO

Towards identification of novel therapeutic candidates, a series of quinazolinone-based acetamide derivatives were synthesized and assessed for their anti-leishmanial efficacy. Amongst synthesized derivatives, compounds F12, F27 and F30 demonstrated remarkable activity towards intracellular L. donovani amastigotes in vitro, with IC50 values of 5.76 ± 0.84 µM, 3.39 ± 0.85 µM and 8.26 ± 1.23 µM against promastigotes, and 6.02 µM ± 0.52, 3.55 ± 0.22 µM and 6.23 ± 0.13 µM against amastigotes, respectively. Oral administration of compounds F12 and F27 entailed >85% reduction in organ parasite burden in L. donovani-infected BALB/c mice and hamsters, by promoting host-protective Th1 cytokine response. In host J774 macrophages, mechanistic studies revealed inhibition of PI3K/Akt/CREB axis, resulting in a decrease of IL-10 versus IL-12 release upon F27 treatment. In silico docking studies conducted with lead compound, F27 demonstrated plausible inhibition of Leishmania prolyl-tRNA synthetase, which was validated via detection of decreased proline levels in parasites and induction of amino acid starvation, leading to G1 cell cycle arrest and autophagy-mediated programmed cell death of L. donovani promastigotes. Structure-activity analysis and study of pharmacokinetic and physicochemical parameters suggest oral availability and underscore F27 as a promising lead for anti-leishmanial drug development.


Assuntos
Antiprotozoários , Leishmania donovani , Leishmaniose Visceral , Cricetinae , Animais , Camundongos , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/metabolismo , Quinazolinonas/farmacologia , Quinazolinonas/uso terapêutico , Quinazolinonas/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Antiprotozoários/farmacologia , Antiprotozoários/uso terapêutico , Acetamidas/farmacologia , Acetamidas/uso terapêutico , Acetamidas/metabolismo , Camundongos Endogâmicos BALB C
3.
Biochem Biophys Res Commun ; 471(1): 205-12, 2016 Feb 26.
Artigo em Inglês | MEDLINE | ID: mdl-26826385

RESUMO

Hypoxia promotes cancer progression, and metastasis. The major protein expressed in hypoxic solid cancer is hypoxia-inducible factor 1 (HIF1). We show that enhanced phosphorylation of a conventional protein kinase C isoform, PKCα, at threonine 638 (T(638)) by hypoxia-mimetic cobalt chloride induces HIF1α in nuclei of gastric epithelial cells (GECs). Moreover, phospho-T(638)-PKCα (P-PKCα) interacts with p300-HIF1α complex in the nuclei of hypoxic GECs and PKCα phosphorylation at T(638) enhances transcriptional activity of HIF1α. High P-PKCα expression in neoplastic gastric cancer biopsy samples as compared to nonneoplastic samples suggests that P-PKCα might act as an indicator of gastric cancer progression.


Assuntos
Núcleo Celular/metabolismo , Cobalto/administração & dosagem , Mucosa Gástrica/metabolismo , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Proteína Quinase C-alfa/metabolismo , Hipóxia Celular/efeitos dos fármacos , Hipóxia Celular/fisiologia , Linhagem Celular , Núcleo Celular/efeitos dos fármacos , Células Cultivadas , Relação Dose-Resposta a Droga , Mucosa Gástrica/efeitos dos fármacos , Humanos , Fosforilação/efeitos dos fármacos , Fosforilação/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA